JDRF is focused on funding and catalyzing research that will lead to a cure of T1D, improving the quality of life and relieving the burden for people living with T1D, and preventing the disease (For more details, see Diabetes 2012; 61:30). JDRF’s focus and funding spans from early exploratory research and preclinical proof-of-principle to proof-of-concept clinical trials through to ensuring regulatory approval and reimbursement across all stages of T1D, while addressing the breadth of challenges in the discovery, development, and delivery of drugs and devices to cure, better treat, and prevent T1D. The Foundation is committed to creating a diversified pipeline of therapeutic candidates at different stages of development to maximize opportunities for success and account for attrition in the R&D process. The earliest stages of the pipeline for several T1D therapies will need to be catalyzed for the foreseeable future with identification of new disease relevant targets and pathways, and there remains a critical need for increased understanding of human T1D disease mechanisms, pathophysiology, and heterogeneity. At the same time, JDRF is focused on progressing more mature opportunities through the pipeline as quickly as possible to deliver both clinically-meaningful benefits and progressive advances on the path to a cure of T1D in the relatively near-term. Breakthrough research, transformative therapies, emerging technologies, translational opportunities, and proof-of-concept clinical trials are prioritized. JDRF partners with the academic sector, other funders and foundations, industry, regulatory agencies, and payers on a world-wide basis and is currently funding research in academia in 18 different countries and has partnered with over 45 different companies in the last decade. Success for JDRF is defined ultimately by the availability of new therapies and devices that we help bring to individuals with T1D or those at risk of developing the disease. Thus, JDRF allocates resources to ensure continuous clinical impact and therapeutic advancements for the largest number of individuals with T1D in the shortest period of time by funding programs ranging from those that are relatively close to the clinic to those that are early in discovery phases and represent potential for significant advancement and impact in longer timeframes.
In type 1 diabetes (T1D), the beta cells in the islets of Langerhans of the pancreas have been destroyed or are non-functional, resulting in a life-time requirement of insulin replacement. Insulin is not a cure for the disease, however, and as used today, is not a guarantee against developing the chronic and devastating complications of kidney failure, blindness, nerve damage, amputation, heart attack and stroke.
To cure T1D will require inducing insulin independence in established disease by restoring functional beta cell mass by either activation of endogenous regeneration of beta cells or exogenous replacement by implantation of a source of glucose-responsive, insulin-secreting cells. Restoration of functional beta cells either by regeneration or replacement will need to be coupled with the prevention of their immune-mediated destruction. For replacement, encapsulation to thwart immune rejection of a replenishable islet or beta cell source is a top JDRF priority. In the case of regenerating beta cells, JDRF is focused on generating new beta cells by stimulating proliferation of residual beta cells, inducing generation of beta cells from precursor cells or alternative mature cells such as alpha cells of the islets, or inducing redifferentiation of dedifferentiated beta cells, and maintaining the survival of extant and newly generated beta cells. At the same time, the immune-mediated destruction of new beta cells must be prevented. The development of beta cell autoantigen specific immunotherapies to induce stable durable immunoregulation is a key JDRF priority.
Until a cure is at hand, JDRF is committed to keeping individuals with T1D healthy and to reducing the daily burden of living with the disease by developing and delivering better options for managing T1D. Improving lives today and preventing diabetic complications in the future requires improving glucose control with devices, including development of closed loop artificial pancreas systems, and with drugs and biologics, including repurposing of existing ones. A subset of individuals with established T1D may gain clinical benefit by increasing the function of their own residual beta cells through various interventions. This is an area of high interest to JDRF and requires further exploration. In recent onset T1D, residual beta cells are usually present and JDRF is focused on enhancing their survival and restoring and maintaining their function with agents targeting beta cell stress and survival and redifferentiation, inflammation, autoimmunity, and glucose control with a long-term goal of inducing durable insulin independence.
As part of its overall strategy, JDRF is also focused on prevention of T1D, representing prevention of symptomatic T1D and long-term insulin dependence JDRF is funding research to further understand the pathogenesis of human T1D and to develop and test interventions to prevent the onset of insulin dependence. Both primary prevention (prevention of beta cell autoimmunity) and secondary prevention (prevention of the onset of symptomatic T1D in at-risk individuals) of T1D are being targeted.
Back to Top
For more information on specific RFAs please visit the JDRF Funding Opportunities and Deadlines.
There are multiple funding mechanisms available for Academia and Industry that will be applied to these opportunities as described in the specific RFAs. Please consult the JDRF Funding Opportunities and Deadlines for the details of the RFA and the application process.
Funding decisions for research proposals submitted in FY2018 will be based on the priorities outlined in the RFA and in this document.
An amendment or waiver of any provision of the Terms and Conditions by JDRF must be in writing to be effective. Notwithstanding the foregoing provisions, nothing in JDRF’s IP policy is intended to, or should be construed to, conflict with Federal or foreign State law governing the Grantee Institution, including any Bayh-Dole or NIH/European Commission obligations that may arise with respect to Inventions resulting from research funded by both JDRF and Federal or foreign State funds. Federal or foreign State law shall govern in the event of any inconsistency with the IP policy.
Therapeutic Goal: A beta cell replacement product capable of delivering insulin independence for at least 1 year with no chronic immunosuppression therapy
Based on recent successes with cadaveric pancreas and islet transplantation, JDRF has shifted its emphasis from cadaveric islet transplantation towards developing replenishable alternative beta cell sources and and cell delivery systems, including encapsulation technologies, to support and protect such cell sources. These two areas address the shortage of human cadaveric donor pancreata and the requirement for lifelong Immunosuppression that restrict the availability of current human pancreas/islet transplantation to a small group of individuals with T1D.
Progress in beta cell and stem cell biology has resulted in protocols for deriving human pancreatic endocrine cell progenitors and surrogate beta cells from human embryonic stem cells (hESC) and adult cells that have been reprogrammed to pluripotency (iPSC). Several companies have applied this knowledge and are poised to develop human stem cell derived pancreatic progenitors and functional surrogate beta cells as potential commercial beta cell replacement products. Meanwhile, xenotransplantation using porcine islets has also advanced and is gaining acceptance as a potential readily available cell source. These advances have positioned hESC/iPSC-derived cells and porcine islets as the most promising replenishable alternative sources of beta cells. As such, developing effective encapsulation approaches for immune protection of these cell sources is currently a major JDRF priority.
JDRF expects the ultimate beta cell replacement products to evolve over a multi-stage development pathway. Each next generation product using either hESC/iPSC-derived cell products or porcine islet cells in a bioengineered scaffold or encapsulation device, is anticipated to improve immune protection to increase durability of activity as they eliminate the burden of immunosuppression. In FY2013, JDRF established an encapsulation consortium involving academia and industry partners to accelerate the development timeline of encapsulated islets by encouraging collaborations among multi-disciplinary experts (bioengineers, chemists, immunologists, transplant researchers, etc.) and by fostering protocol standardization and independent replication of promising results. Research applications in the area of Encapsulation (except training grants) that are selected for funding will be required to participate in the JDRF Encapsulation Consortium.
JDRF Priority Areas in FY2018
Inquiries: Esther Latres, Ph.D. (email@example.com; Tel: 212-479-7624)
Therapeutic Goal: Drugs or biologics that promote the survival, health, and function of beta cells for individuals at risk (stages 1 and 2), recently diagnosed (stage 3) and established T1D with residual beta cell function. Drugs or biologics that restore functional beta cells to achieve insulin independence in established T1D.
It is becoming increasingly well appreciated that beta cells are not passive victims in the development of T1D. Beta cell stress with activation of the unfolded protein response (UPR) plays a role in initiating loss of beta cell function and mass in T1D and conceivably triggering or potentiating the beta cell-specific autoimmune response. Beta cell survival therapies are envisioned to prevent loss of beta cell function and/or restore function of beta cells or dedifferentiated beta cells in the at-risk (stage 1 and stage 2) and new onset (stage 3) stages of T1D and to preserve residual beta cell function in individuals with established T1D with significant residual beta cell mass.
Beta cell regenerating therapies that increase and/or restore beta cell function will be critical for achieving insulin independence in people with T1D. Regenerating therapies include: a) therapies to promote the expansion (replication, division and growth) of residual mature beta cells; b) therapies targeting beta cell neogenesis by promoting the differentiation of an endogenous adult stem cell or precursor cell or the conversion of an alternative mature cell type, such as an islet alpha cell, into a beta cell, and c) therapies to promote expansion and then subsequent re-differentiation of dedifferentiated beta cells. To protect newly regenerated beta cells, beta cell survival therapies may also be required.
In parallel with these therapeutic objectives, JDRF has prioritized the discovery and validation of candidate biomarkers of early beta cell stress, dysfunction and loss to aid in the design and execution of more efficient and effective clinical studies. Biomarkers or imaging to detect and quantify beta cell mass and function, islet inflammation, and newly generated beta cells could have a direct impact on the success of beta cell replacement and regeneration. Applications of such beta cell biomarkers to the development of innovative clinical testing approaches that shorten and improve the design of clinical studies using beta cell therapies is a high priority for JDRF.
Inquiries: Patricia Kilian, Ph.D. (firstname.lastname@example.org) or Andrew Rakeman, Ph.D. (email@example.com; Tel: 212-479-7664)
Therapeutic goal: The JDRF Immunotherapies program is committed to facilitating the development of disease modifying vaccines, drugs and biologics that act via inducing, restoring and maintaining durable beta cell-specific immune tolerance. The desired clinical outcomes are to prevent or delay disease in people at risk of T1D and to halt or reverse progression after onset that tangibly impact quality of life measures in those impacted, such as stabilizing dysglycemia and delaying insulin needs prior to disease onset, and lowering insulin needs, improving time-in-range and reducing hypoglycemic events after disease onset.
Development of tolerance delivery systems (TDS) as therapeutics that can deliver autoantigens to the immune system in a tolerogenic fashion, is a high priority area of this program. In addition, antigen non-specific therapies targeted at purging pathogenic T cells or deviation/maintenance therapies targeted at creating and sustaining tolerogenic environments are of interest for evaluation as part of potential combination therapies. Increasing data in the field suggests that targeting multiple and distinct pathways of the immune system in different subsets of subjects will likely be needed to achieve the maximal desired impact of immune (and other) therapies on altering disease course. Therefore, addressing the challenges of disease heterogeneity and identifying disease endotypes with biomarkers is also a key focus area of the immunotherapies program. The establishment of robust immune biomarkers that enable effective stratification of subjects in clinical trials, as well as those that can predict and measure therapeutic responses to different agents should greatly facilitate and expedite the evaluation of candidate therapies in T1D. To this end, utilization of resources such as the JDRF nPOD (www.jdrfnpod.org) and the JDRF Biomarker Working Group (http://www.t1dbiomarkers.org/), is encouraged across projects whenever possible.
Inquiries: Simi Ahmed, Ph.D. (firstname.lastname@example.org; Tel: 212-479-7679)
Therapeutic Goals: Prevention or delay of onset of beta cell-specific autoimmunity (Stage 1) or clinical T1D (Stage 3) in individuals at-risk of developing T1D
The incidence of T1D has been increasing about 3-4% annually for the last several decades and at even higher rates in the age range 1-5 years in many countries. JDRF is focused on both primary prevention (prevention of beta cell autoimmunity – Stage 1) and secondary prevention (prevention of clinical disease – Stage 3) of T1D. Developing childhood population-based primary and secondary prevention interventions is prioritized as are approaches to prevent T1D in relatives of affected individuals. Vaccine-based approaches (diabetes-related viral vaccines, beta cell autoantigen-specific immunoregulatory vaccines, or vaccines to augment or accelerate global microbiome-induced immunoregulation in infancy) are prioritized for primary prevention. Secondary prevention will require cost-effective childhood population-based approaches to screen for risk and precise staging of disease progression to allow tailored, stage-specific interventions to prevent symptomatic T1D, which may include targeting: islet inflammation, beta cell-specific autoimmunity, beta cell survival, and/or dysglycemia, as detailed in the appropriate therapeutic area descriptions. There is growing evidence that the microbiome is disregulated in individuals at risk for T1D and approaches to understand and translate these observations into therapeutic approaches are encouraged. Further insights into the pathogenesis, staging, and heterogeneity of human type T1D will be required to effectively develop and deliver preventive interventions. Further insights into JDRF’s strategy for Prevention are described at: http://www.jdrf.org/blog/2016/12/09/top-t1d-advances-2016/
Inquiries: Jessica Dunne, Ph.D. (email@example.com; Tel: 212-479-7595)
Therapeutic Goal: Artificial pancreas systems that improve/restore glucose regulation with significant reduction in HbA1c, significant reduction in hypoglycemia, and improved quality of life by reducing the burden on the individual and caregiver.
Research consistently shows that glycemic control directly impacts the risks associated with diabetes, including hypoglycemia, heart disease, kidney disease, eye disease, and peripheral nerve disease. It is well documented that elevated mean glucose is directly linked to the formation of these diabetic complications. Despite considerable progress in treatments and technology, glycemic control goals for people with T1D often remain out of reach across all ethnicities and social strata. New technologies to measure glucose and dispense insulin have matured and the potential exists to apply new technology to enhance control, as well as to couple that technology to insulin delivery and controller algorithms to automatically regulate blood sugar levels. JDRF is committed to accelerating the development of sequential stages of automated artificial pancreas device systems. The first generation hybrid closed loop artificial pancreas systems that automatically dispense insulin, but require the wearer to bolus at mealtimes, is now available in the USA and likely to be globally shortly. Our research focus is now on approaches to increase functionality towards next generation systems that will further improve glucose control and minimize user burden, including the development of more physiological systems involving hepatic delivery of insulin. In addition JDRF is interested in furthering novel technologies and approaches to improving clinical care through data-driven clinical decision support.
Inquiries: Sanjoy Dutta, Ph.D. (firstname.lastname@example.org; Tel: 212-479-7668)
Therapeutic Goal: Non-device (ex: drugs) based approaches that improve/restore glucose regulation with significant reduction in HbA1c, significant reduction in hypoglycemia, and improved quality of life.
Non-device-based approaches to improve glucose control are required in T1D. Novel insulins including faster-acting, glucose-responsive and liver targeted insulins, and improved delivery of insulin to more closely mimic physiologic insulin release, speed and duration of action are prioritized. An additional priority would be for mechanistic studies of non-insulin metabolic therapies to help understand potential benefit in T1D, including a focus on patient stratification and sub-populations with unmet medical needs.
It should be noted that optimal glucose regulation is also important to preserve the viability of either regenerated or transplanted beta cells and to preserve functional beta cell mass in recent onset type 1 diabetes and in the pre-diabetes stages of the disease.
Therapeutic Goals: Agents that prevent, arrest and reverse diabetic kidney and diabetic eye diseases.
Insulin replacement therapy for T1D is not a cure, and is often insufficient to prevent the onset of debilitating and/or life-threatening diabetic complications, including loss of vision and kidney disease, among others. Despite significant advances in glucose monitoring and insulin therapy, people with diabetes still spend significant portions of the day with hyperglycemia and fail to achieve recommended glucose control, placing them at risk for the development of diabetic complications. Unfortunately, even in the face of improved glucose control, some people progress to develop diabetes complications, possibly through genetic predisposition and other yet unidentified factors. JDRF is focused on discovering and developing therapies to prevent, arrest, or reverse diabetic complications of the eye and kidney, with a priority for intervening at earlier stages of disease progression.
Important Note: Although JDRF recognizes the importance of research investigating other complications of diabetes, JDRF priorities for FY2018 do not include atherosclerosis and peripheral vascular diseases, myocardial infarction and stroke, wound healing, analgesia and pain research, neuropathy, embryopathy, cognitive impairment, depression, periodontal disease and osteoporosis.
Inquiries: Marlon Pragnell, Ph.D. (email@example.com; Tel: 212-479-7690)